PCN309 Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Single-Agent Belantamab Mafodotin (BELAMAF)

Autor:	Juliette Meunier, Boris Gorsh, L. Eliason, Antoine Regnault, Sandhya Sapra, D. Kleinman, A. Loubert
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry Health Policy Public Health Environmental and Occupational Health medicine.disease Outcome (game theory) Internal medicine Relapsed refractory Medicine Single agent In patient business Multiple myeloma
Zdroj:	Value in Health. 23:S477
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::794e311791caf0dd12cba974089f9c69 https://doi.org/10.1016/j.jval.2020.08.446 Zobrazit plný text záznamu Full Text from ScienceDirect